α7 nAChRs have attracted interest as potential therapeutic targets for cognitive and attentional disorders such as schizophrenia, Alzheimer's disease and autism (Bertrand et al., 2015). This evidence concerns the gene CHRNA7 and early-onset autosomal dominant Alzheimer disease.